Abstract: Parthenogenesis is the process in which an
Introduction
Embryonic stem (ES) cells can be isolated from the inner cell mass (ICM) of blastocyst stage preimplantation embryos. These cells can self-renew and they retain the ability to differentiate into one or more specialized cell types in vitro and in vivo. Because of their unique properties, ES cells hold great promise for use in cell replacement therapy and in drug discovery. Creation of cell replacement products from ES cells that are genetically matched to patients' tissues is, however, hampered by immunological barriers created by the major histocompatibility complex (MHC; or human leukocyte antigen, HLA, in humans) antigen. Parthenogenesis and somatic cell nuclear transfer (SCNT) are two methods by which ES cells can be derived that are genetically matched to the oocyte donor and somatic cell donor, respectively. Several studies have demonstrated that autologous ES cells can be derived via SCNT in mice [1] [2] [3] , monkeys [4, 5] and humans [6] ; however, the technology used to -MHC matched ES cell lines. Parthenogenesis is the event by which an oocyte is activated to develop to the blastocyst stage without fertilization. Ovulated mature oocytes can be activated parthenogenetically by heat shock, electric pulses, or chemical inducement (e.g., calcimycin, strontium chloride); togethin inhibition of polar body extrusion and a diploid oocyte. Derivation of parthenogenetic ES (pES) cell lines from ES cell lines from fertilized blastocysts [9] . Mouse pES cells can be chimerized to nearly all tissues, but rarely to germ cells, when injected into mouse blastocyst embryos generate teratomas, contributing to all three germ layers [11] . Mouse ES cells derived from fertilized embryos can develop into pups when they are injected into tetraploid blastocysts [12] . In contrast, although recently Kono et al. recently generated live-born pups from mouse parthenogenetic embryos, by altering imprinted genes via nuclear transfer [13] , pES cells can only develop to the early heart beating stage as a result of impaired paternal imprinted genes [14] . Parthenogenetic activation can be performed at meiosis I or meiosis II, which results in distinct patterns of homozygosity and heterozygosity in the resulting embryos [15] . The pattern of homozygosity and heterozygosity of pES cells derived from these embryos -morphism (SNP) analysis, which determines whether the Importantly, heterozygous pES cells that carry the full complement of MHC antigens of the oocyte donor may serve as a potential source of histocompatible cells or tissues for cell replacement therapy.
In this review, we summarize the mechanisms underlying the distinct heterozygous patterns of pES cells from embryos that have been activated parthenogenetically during the various stages of meiosis and describe the creation of histocompatible mouse pES cells derived from such embryos. Human pES cell lines have been established [16, 17] and similar mechanisms dictating heterozygosity have been observed in these cells [18] . Therefore, we anticipate the future use of human pES cells as a source of histocompatible cells and tissues for cell replacement therapy.
Derivation of p(MII) ES Cells
Immature oocytes arrested at the diplotene stage of meiosis I carry 20 sets of two homologous chromosomes (bivalents). During meiosis I, chromosome crossing over events occur distant from the centromere; then homologue segregation occurs and the paternal and maternal oocytes enter meiosis II and arrest at the metaphase stage until fertilization (MII oocytes). When MII oocytes are activated parthenogenetically and the second polar body extrusion is prevented by cytochalasin B, an indiploid and develops to the blastocyst stage. pES cells derived from these blastocysts, called p(MII) ES cells, retain pericentric homozygosity with distal heterozygosity length of chromosome 17 (83.10 cM) [19] , the mouse H-2 MHC region is located on the proximal region of chromosome 17 (position 18.40-20.43 cM) [20] . Theoretically, the H-2 MHC region in p(MII) ES cells will be homozythis, we collected unfertilized MII oocytes from C57BL/6 development by preventing the second polar body extrusion [15] . Of 72 p(MII) ES cell lines derived from these embryos, 24 lines (33%) had restored heterozygosity, selected 17 p(MII) ES cell lines for high-resolution genome-wide SNP analysis using a standard panel of 768 mouse markers spaced across the genome. This analysis revealed that p (MII) ES cells showed a high degree of heterozygosity, and the heterozygosity increased in pro-2A). Interestingly, the p(MII) ES cells showed a much lower degree of homozygosity than we anticipated, indicating that recombination events before meiosis II render the majority of loci in p(MII) ES cells heterozygous. When they were engrafted and formed teratomas. When these ES cells were engrafted, though not to C57BL/6 and CBA inbred mice. Thus, the p(MII) ES cells were completely immune matched to the oocyte donor.
Derivation of p(MI) ES Cells
ment with cytochalasin D after chromosome crossing over events in meiosis I during oocyte maturation, the parental chromosomes fail to segregate and the oocytes carry two pairs of parental chromosomes at the metaphase stage of meiosis II (tetraploid). When the oocytes are activated parthenogenetically, they then extrude the second polar body to become diploid. pES cells derived from embryos developed from such oocytes are called p(MI) ES cells. Because parental chromosome pairs fail to segregate, p(MI) ES cells retain pericentromeric het-1B). We found that 21 out of 23 p(MI) ES cell lines (91%) showed heterozygosity within the H-2 MHC loci accordthe centromere, with distal telomeric regions of homocells after injection into mice was same as that of p(MII) ES cells. Of note, p(MI) ES cells have a higher potential for the derivation of histocompatible cells and tissues for therapeutic applications, because they harbor a much higher frequency of heterozygosity than p(MII) ES cells,
Derivation of p(hap) ES Cells
Haploid embryos can be obtained when unfertilized mature oocytes are activated parthenogenetically and extrusion of the second polar body is allowed to occur. 
Derivation of Human pES Cells
Derivation of parthenogenetic human (h) pES cell et al. [16] . Subsequently, two additional groups claimed derivation of hpES cell lines using different methodologies, namely, a combination of chemical and electrical activation of oocytes [22] , and spontaneet al. isolated homozygous HLA donor-matched hpES cell lines from human parthenogenetic blastocysts created via chemical activation [17] . The human ES cell line (SCNT-hES-1) which was originally claimed to be derived by SCNT [24] , is reported to be an inadvertently derived parthenogenetic line. All of these lines were derived by inhibiting the second polar body extrusion, resulting in in vitro development of pMII blastocysts, at approximate efmethods, and 7% by spontaneous activation of the ooat a frequency of 6/11 [16] 
Conclusion
In this review, we summarized the derivation of MHCmatched parthenogenetic mouse and human ES cells from embryos that are activated parthenogenetically at various stages of meiosis. p(MI) ES cells show a much higher frequency of heterozygosity than p(MII) ES cells, suggesting that p(MI) ES cells may be a better source of MHC-matched cells or tissues. According to the HLA matching results reported by Nakajima et al. [25] , if parthenogenetic human ES cell lines are established from 55 randomly selected oocyte donors, 80% of pacomplete matching at all three HLA loci in the Japanese population. This estimate is higher than that of Taylor et al. [26] , who used HLA data from cadaveric organ donors and kidney transplantation waiting lists in the United Kingdom. A likely reason for this difference is that the Japanese population shows relatively low ethnic diversity compared to that of the UK. The derivation of human pES cells may reduce the number of ES cell lines required for the matching of HLA loci, and human HLA-matched pES cells may have high potential for therapeutic use in regenerative medicine, if they are proven to be safe.
